severe pneumonia
Conditions
Interventions
experimental group:After enrollment, the subjects entered the dosing observation period and received conventional treatment + study drug treatment (colimycin)
Sponsors
Department of Critical Care Medicine of West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The subject or the legal representative of the subject fully understands the purpose, nature, methods and possible adverse reactions of the trial, and is 18 years and over, and signs an informed consent form; 2. Severe pneumonia caused by carbapenem-resistant gram-negative bacteria infection is diagnosed by clinical symptoms, laboratory examination and imaging examination; 3. After applying the best clinical treatment plan available, it is clinically judged that the treatment is invalid or the disease has progressed.
Exclusion criteria
Exclusion criteria: 1. Allergy to macrolide drugs; 2. Patients with severe gastrointestinal diseases that affect the intake and absorption of study drugs, including but not limited to: severe diarrhea; patients with abnormal liver function and Child-Pugh score of C; 3. Those who are participating in other clinical research within 4 weeks before screening; 4. The investigator believes that the subject has any other circumstances that cannot allow this research protocol to proceed safely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| the length of hospital stay;the length of ICU stay; | — |
Countries
China
Contacts
Public ContactWu Qin
Department of Critical Care Medicine of West China Hospital, Sichuan University
Outcome results
None listed